Immunoadsorption columns have been widely used to purify specific antibodies and antigens. Plasma is removed by apheresis and passed through an adsorption medium to remove harmful antibodies before being re-infused into the patient in immunoadsorption columns.
Immunoadsorption columns are increasingly being recognised as a promising and low-risk treatment option for a wide range of cardiac, haematological, neurological, and other disorders. Immunoadsorption columns are also becoming more popular as a treatment option for a variety of chronic and acute disorders, including multiple sclerosis, Guillain-Barre syndrome, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and autoimmune encephalitis.
Request Brochure @
https://www.futuremarketinsights.com/reports/brochure/rep-gb-7538
Plasma components are separated using immunoadsorption columns by adsorber systems that are designed to selectively bind immunoglobulins.
Tryptophan, protein A, and polyclonal sheep antibodies, for example, can be used alone with immunoadsorption columns. Immunoadsorption columns containing protein A or sheep antibodies allow for more selective immunoglobulin removal as well as regenerating mechanisms.
Most modern immunoadsorption columns have two columns that alternate between loading and regeneration cycles, which saves time and allows for larger blood volumes to be processed.
Immunoadsorption Columns Market: Drivers and Restraints
One of the major factors driving the immunoadsorption columns market over the forecast period is the increasing prevalence and recurrence of cardiac, neurological, dermatological, and rheumatological anomalies. According to the Centers for Medical and Medicare Services, the global prevalence of rheumatoid arthritis is 0.5% to 2.0%, with a female to male ratio of 2.5:1. Rheumatoid arthritis is known to cause significant disability and has a higher-than-expected mortality rate. However, uncertainties in the available treatment for this disorder, as well as high treatment costs, are some of the factors that are likely to limit the growth of the immunoadsorption market.
One of the major factors driving the immunoadsorption columns market over the forecast period is the increasing prevalence and recurrence of cardiac, neurological, dermatological, and rheumatological anomalies. According to the Centers for Medical and Medicare Services, the global prevalence of rheumatoid arthritis is 0.5% to 2.0%, with a female to male ratio of 2.5:1. Rheumatoid arthritis is known to cause significant disability and has a higher-than-expected mortality rate. However, uncertainties in the available treatment for this disorder, as well as high treatment costs, are some of the factors that are likely to limit the growth of the immunoadsorption market.
The Asia Pacific immunoadsorption columns market, excluding Japan, is expected to grow at a significant CAGR due to an increase in the number of products offered by the key players. Throughout the forecast period, Europe is expected to hold the second-largest share of the global immunoadsorption columns market.
Request Methodology @
https://www.futuremarketinsights.com/request-report-methodology/rep-gb-7538
Immunoadsorption Columns Market: Key Players
The global market for immunoadsorption columns is highly consolidated. Baxter International Inc., Fresenius Kabi AG, Terumo Corporation, Asahi Kasei Corporation, POCARD Ltd., Glycorex Transplantation AB, and Miltenyi Biotec are some of the key players in the global immunoadsorption columns market.
The research report provides an in-depth analysis of the market and includes thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also includes projections based on an appropriate set of assumptions and methodologies. The research report analyses and provides information based on market segments such as geography, application, and industry.
Immunoadsorption Columns Market: Segmentation
The global immunoadsorption columns market can be segmented on the basis of indication, end user and geography.
Based on indication, the global immunoadsorption columns market is segmented as:
- Cardiology
- Dilated Cardiomyopathy (DCM)
- Diabetic cardiomyopathy
- Pulmonary hypertension
- Haematology
- Haemophilia with inhibitors against factor VIII or IX
- Thrombotic-thrombocytopenic purpura (TTP)
- Chemotherapy-induced haemolytic-uremic syndrome (c-HUS)
- Anti-phospholipid syndrome
- Transplantation
- Anti-HLA hyper-immunisation
- Acute Humoral Rejection (AHR)
- Kidney transplantation
- Heart transplantation
- Dermatology
- Pemphigus vulgaris
- Pemphigus foliaceus
- Bullous Pemphigoid
- Pemphigoid Gestationis
- Epidermolysis bullosa aquisita
- Neurology
- Guillain-Barré syndrome (GBS)
- Myasthenia gravis (MG)
- Chronic Inflammatory Demyelinising Polyneuropathy (CIDP)
- Multiple sclerosis
- Lambert-Eaton syndrome
- Stiff person syndrome
- Morvan’s syndrome
- Rheumatology
- Systemic Lupus Erythematodes (SLE)
- Wegener’s granulomatosis
- Rheumatoid arthritis
- Nephrology
- Rapidly Progressive Glomerulonephritis (RPGN)
- Goodpasture syndrome
- Recurrent Focal Segmental Glomerulosclerosis (FSGS)
Based on end user, the global Immunoadsorption Columns Market is segmented as:
- Hospitals
- Specialty Clinics
- Academic & Research Centres
Ask An Analyst @
https://www.futuremarketinsights.com/ask-question/rep-gb-7538
About Us
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs